Market Overview

Sagent Pharmaceuticals Announces Launch of Nafcillin for Injection, USP

SCHAUMBURG, Ill., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of Nafcillin for Injection, USP, in two vial presentations and one pharmacy bulk package bottle; all three are latex-free and preservative-free. According to IMS, for the 12 months ending September 2012, the US market for Nafcillin approximated $62 million. As with all products in Sagent's portfolio, Nafcillin features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

About Nafcillin for Injection, USP

Nafcillin for Injection, USP is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. It should not be used in infections caused by organisms susceptible to penicillin G.

The package insert, which is available at www.sagentpharma.com, contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent (847) 908-1605
 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional